vTv Therapeutics reports additional positive PhII data; Shanghai Henlius prices $410 million IPO at bottom of range
→ vTv Therapeutics — focused on the development of oral small molecule drug candidates — has unveiled additional positive data from its Phase II Simplici …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
